Reports Q4 revenue $11.31M, consensus $11.14M. “As we reflect on the accomplishments of 2023, it has been a great year for CVRx. We are proud to have sustained the momentum in driving the adoption and utilization of Barostim, resulting in a 97% annual increase in U.S. heart failure revenue,” said Nadim Yared, President and CEO of CVRx. “Additionally, we achieved significant milestones, such as the expansion of Barostim labeling and CMS’ OPPS ruling assigning Barostim to the New Technology payment code. We believe these changes will enhance access to our therapy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVRX:
- Cvrx, Inc. (CVRX) Q4 Earnings Cheat Sheet
- CVRx price target raised to $31 from $30 at Canaccord
- CVRx price target raised to $35 from $32 at Lake Street
- CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
- CVRx price target raised to $30 from $24 at Craig-Hallum
